The trouble with approving treatments which don’t work very well (according to Novartis, MSB’s former development partner) is that it diverts valuable resources from treatments which do work. And at the eye watering cost of $70k a pop, that is some resources.
Lets face facts. If stems were going to form even a small part of the Covid answer, Novartis would not have walked away, after securing the prime spot to partner and develop this treatment. Moreover, the FDA would have, at a minimum, given EUA just to see how things went. It speaks volumes that the FDA told them to go away and do further trials.
It really begs the question, apart from the cult followers and the odd paid MSB consultant, who actually thinks stems are the answer?
The trouble with approving treatments which don’t work very well...
-
- There are more pages in this discussion • 774 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 211966 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 136540 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |